Skip to Content

Notice

Manufacturer of Controlled Substances; Notice of Application

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 4298

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 17, 2006, Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

DrugSchedule
Codeine-N-oxide (9053)I
Difenoxin (9168)I
Dihydromorphine (9145)I
Morphine-N-oxide (9307)I
Norlevorphanol (9634)I
Normorphine (9313)I
Tetrahydrocannabinols (7370)I
Nabilone (7379)II
Alfentanil (9737)II
Amphetamine (1100)II
Ecgonine (9180)II
Codeine (9050)II
Dextropropoxyphene, bulk (9273)II
Dihydrocodeine (9120)II
Diphenoxylate (9170)II
Diprenorphine (9058)II
Etorphine HCL (9059)II
Fentanyl (9801)II
Hydrocodone (9193)II
Hydromorphone (9150)II
Levo-alphacetylmethadol (9648)II
Levorphanol (9220)II
Meperidine (9230)II
Methadone (9250)II
Methadone intermediate (9254)II
Methamphetamine (1105)II
Methylphenidate (1724)II
Metopon (9260)II
Morphine (9300)II
Opium extracts (9610)II
Opium fluid extract (9620)II
Opium tincture (9630)II
Opium, granulated (9640)II
Opium, powdered (9639)II
Oxycodone (9143)II
Oxymorphone (9652)II
Noroxymorphone (9668)II
Phenazocine (9715)II
Alfentanil (9737)II
Remifentanil (9739)II
Sufentanil (9740)II
Thebaine (9333)II

The firm plans to manufacture the listed controlled substances for internal use and for sale to other companies.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than April 2, 2007.

Start Signature

Dated: January 23, 2007.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

End Signature End Preamble

[FR Doc. E7-1402 Filed 1-29-07; 8:45 am]

BILLING CODE 4410-09-P